|
Dr. McCutchan graduated from Yale University Medical School, completed his residency training in Internal Medicine at Vanderbilt and Yale-New Haven Hospital, and was an Infectious Diseases Fellow at UCSD. After joining the UCSD Faculty, he received a Milbank Fellowship to study epidemiology at the School of Hygiene and Tropical Medicine of the University of London After receiving a Master of Science degree, he was a Research Fellow in Genitourinary Medicine at the Middlesex Hospital , London .
Research Interests
Since 1982, he has focused his research on the clinical epidemiology, management and neurological effects of HIV. Since 1986, the California Collaborative Treatment Group (CCTG), which he founded and directed until 2003, coordinated the efforts of five universities (UCSD, UC Irvine, University of Southern California , Harbor/ UCLA and Santa Clara Valley /Stanford) in clinical studies of AIDS. The CCTG initially investigated the epidemiology and pathogenesis of AIDS related opportunistic infections (Pneumocystis, Toxoplasma, Mycobacterium Avium, Cytomegalovirus, and Cryptococcus). CCTG studies proved that (1) adjunctive steroids halved the mortality from PCP, (2) MAC was treatable with combinations of clarithromycin and ethambutol and preventable with weekly azithromycin, and (3) cryptococcal meningitis treatable and preventable with oral antifungals (fluconazole and 5-Flourocytosine). More recently, CCTG have focus on the role of viral load measures, phenotypic resistance assays, and therapeutic drug monitoring in management of HIV.
In the AIDS Clinical Trials Group (ACTG), he chaired both the Mycobacterial Subcommittees of the Complications Research Agenda Committee (RAC) and is a current member of Complications RAC.
Since 1996, he has co-chaired Study 362 which is tracking the long term clinical and immunologic effects of immune restoration by HAART. He is designing one of the first international studies in the ACTG (5225), a Phase II trial of very high doses of oral fluconazole for cryptococcal meningitis.
Dr McCutchan has co-directed the HIV Neurobehavioral Research Center (HNRC), a multidisciplinary research effort studying the HIV in the nervous system. He has focused on the origins, dynamics, and treatment of HIV in the brain as measured in cerebrospinal fluid. He has also contributed to a numerous papers describing the neurology and neuropsychology of HIV
He co-directs the NIH K-30-sponsored CREST (Clinical Research Enhancement Thru Supplemental Training) Program. This program provides methodological training to postdoctoral fellows and junior faculty at UCSD who are interested in patient-oriented research. He both directs and teaches courses in design of clinical trials and the ethics and regulation of clinical research. He helped to develop a CREST-associated Masters of Advanced Studies in Clinical Research degree program and has chaired the thesis committees of many of its graduates.
Recently, he has become involved in several international training and research activities. He has directed the UCSD International Military HIV Training Program, sponsored by the Department of Defense for training for military medical personnel dealing with HIV, for 4 years. He directs the UCSD Program for PEPFAR Support to the Uniformed Services of Ethiopia which provides training and support to the Ethiopian miliary, police, and prison medical providers implementing PEPFAR-sponsored HIV care including antiretroviral therapy. He also has organized training for international volunteers in conjunction with the Peace Corps and UCSD extension and for laypersons involved in prevention and control of HIV and TB along the US-Mexican Border.
Selected Publications
Richardson JL, Milam J, McCutchan JA , Stoyanoff S, Bolan R, Weiss J, Kemper C, Larsen RA, Hollander H, Weismuller P, Chou CP, Marks G. Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS, 18(8): 1179-1186, 2004.
Letendre SL, McCutchan JA , Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ, and the HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol, 56(3):416-23, 2004.
Mathews WC, Caperna JC, Barber RE, Torriani FJ, Miller LG, May S, McCutchan JA. Incidence of and risk factors for clinically significant methicillin-resistant staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr, 40(2):155-160, 2005.
Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother, 49(6):2504-2506, 2005.
Pillai SK, Kosakovsky Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, Letendre S, Smith DM, Gunthard HF, Grant I, Marcotte TD, McCutchan JA, Richman DD, Wong JK. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain, 1872-83. 2006. |
